An unsymmetrically substituted porphyrin, 5-[4-(3-amino)-n-propyloxyphenyl]-10,15,20-tris-(4-carboxymethyleneoxyphenyl)porphyrin, was synthesized and coupled with p-NCS-benzyl-DOTA [p-isothiocyanato-benzyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid] for exploring its possible potential in targeted tumor therapy. The porphyrin-DOTA conjugate was radiolabeled with 90Y, obtained from a 90Sr/90Y electrochemical generator, developed in-house. Biodistribution studies performed in Swiss mice bearing fibrosarcoma tumor showed good tumor uptake (∼3.4% injected activity in per g of tumor) within 30 minutes postinjection. The tumor activity decreased with the progress of time, however, tumor to blood and tumor to muscle ratios considerably increased at 4 days postadministration owing to the clearance of the initially accumulated activities from the nontarget organs. The nonaccumulated activity exhibited major clearance through renal pathway.
OyenWJG, BodeiL, GiammarileFet al.Targeted therapy in nuclear medicine - current status and future prospects. Ann Oncol, 2007; 18:1782.
4.
GabrielM, AndergassenU, PutzerDet al.Individualized peptide-related-radionuclide therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients. Q J Nucl Med Mol Imaging, 2010; 54:92.
5.
KwekkeboomD, Mueller-BrandJ, PaganelliGet al.Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med, 2005; 46:62S.
6.
DaviesAJ. Radioimmunotherapy for B-cell lymphoma: Y-90 ibritumomab tiuxetan and I-131 tositumomab. Oncogene, 2007; 26:3614.
7.
VolkertWA, GoecklerWF, EhrhardtGJet al.Therapeutic radionuclides: Production and decay property considerations. J Nucl Med, 1991; 32:174.
8.
DasT, PillaiMRA. Options to meet the future global demand of radionuclides for radionuclide therapy. Nucl Med Biol, 2013; 40:23.
9.
ChakravartyR, DashA, PillaiMRA. Availability of yttrium-90 from strontium-90: A nuclear medicine perspective. Cancer Biother Radiopharm, 2012; 27:621.
10.
JongMD, BreemanWAP, ValkemaRet al.Combination radionuclide therapy using 177Lu and 90Y-labeled somatostatin analogs. J Nucl Med, 2005; 46:135.
Therapeutic Radionuclide Generators: 90Sr/90Y and 188W/188Re generators. IAEA Technical Report Series No. 470, IAEA Vienna, 2009. www-pub.iaea.org/MTCD/publications/PubDetails.asp?pubId=8045. 2012 October 14.
13.
FrochotC, Di StasioB, Barberi-HeyobMet al.New glycosylated porphyrins for PDT applications. Oftalmologia, 2003; 56:62.
14.
BanfiS, CarusoE, CaprioliSet al.Photodynamic effects of porphyrin and chlorin photosensitizers in human colon adenocarcinoma cells. Bioorg Med Chem, 2004; 12:4853.
15.
GianferraraT, BergamoA, BratsosIet al.Ruthenium-porphyrin conjugates with cytotoxic and phototoxic antitumor activity. J Med Chem, 2010; 53:4678.
16.
SamarooD, VinoduM, ChenXet al.meso-Tetra(pentafluorophenyl)porphyrin as an efficient platform for combinatorial synthesis and the selection of new photodynamic therapeutics using a cancer cell line. J Comb Chem, 2007; 9:998.
17.
HiramatsuR, KawabataS, MiyatakeSet al.Application of a novel boronated porphyrin (H2OCP) as a dual sensitizer for both PDT and BNCT. Lasers Surg Med, 2011; 43:52.
18.
RennerMW, MiuraM, EassonMWet al.Recent progress in the syntheses and biological evaluation of boronated porphyrins for boron neutron-capture therapy. Anticancer Agents Med Chem, 2006; 6:145.
19.
NakajimaS, TakemuraT, SakataI. Tumor-localizing activity of porphyrin and its affinity to LDL, transferrin. Cancer Lett, 1995; 92:113.
20.
LukšienėZ. Photodynamic therapy: Mechanism of action and ways to improve the efficiency of treatment. Medicina, 2003; 39:1137.
21.
MaziereJC, SantusR, MorlierePet al.Cellular uptake and photosensitizing properties of anticancer porphyrins in cell membranes and low- and high-density lipoproteins. J Photochem Photobiol, 1990; 61:6.
ChakravartyR, PandeyU, ManolkarRBet al.Development of an electrochemical 90Sr-90Y generator for separation of 90Y suitable for targeted therapy. Nucl Med Biol, 2008; 35:245.
24.
AdlerAD, LongoFR, ShergalisW. Mechanistic investigations of porphyrin synthesis. Preliminary studies on meso-tetraphenylporphin. J Am Chem Soc, 1964; 86:3145.
PandeyU, DhamiPS, JagesiaPet al.Extraction paper chromatography technique for the radionuclide purity evaluation of 90Y for clinical use. Anal Chem, 2008; 80:801.
27.
DasT, ChakrabortyS, SarmaHDet al.A novel 177Lu-labeled porphyrin for possible use in targeted tumor therapy. Nucl Med Biol, 2010; 37:655.
28.
DasT, ChakrabortyS, SarmaHDet al.170Tm-EDTMP: A potential cost effective alternative to 89SrCl2 for bone pain palliation. Nucl Med Biol, 2009; 36:561.
29.
RaoAV, AkabaniG, RizzieriDA. Radioimmunotherapy for non-Hodgkin's lymphoma. Clin Med Res, 2005; 3:157.
30.
KunikowskaJ, KrólickiL, Hubalewska-DydejczykAet al.Clinical results of radionuclide therapy of neuroendocrine tumors with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: Which is better. Eur J Nucl Med Mol Imaging, 2011; 38:1788.
31.
OzlemN, KucukON, SoydalC, LacinSet al.Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for resectable primary and metastatic liver tumors. World J Surg Oncol, 2011; 9:86
32.
SamantaSK. Recovery, purification and quality evaluation of 90Sr. Production of long lived parent radionuclides for generators: 68Ge, 82Sr, 90Sr and 188W. IAEA, 2010; 49–78. www-pub.iaea.org/MTCD/publications/PubDetails.asp?pubId=8268. 2012 October 14.
DasT, ChakrabortyS, SamuelGet al.A novel [186/188Re]-labelled porphyrin for targeted radiotherapy. Nucl Med Commun, 2001; 22:1101.
35.
SarmaHD, DasT, BanerjeeSet al.Studies on efficacy of a novel 177Lu-labeled porphyrin derivative in regression of tumors in mouse model. Cancer Biother Radiopharm, 2011; 4:150.
36.
SarmaHD, DasT, BanerjeeSet al.Biologic evaluation of a novel 188Re-labeled porphyrin in mice tumor model. Cancer Biother Radiopharm, 2010; 25:47.
